Form 8-K - Current report:
SEC Accession No. 0001193125-23-088948
Filing Date
2023-04-03
Accepted
2023-04-03 08:00:55
Documents
12
Period of Report
2023-03-30
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d491593d8k.htm   iXBRL 8-K 23984
  Complete submission text file 0001193125-23-088948.txt   141786

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20230330.xsd EX-101.SCH 2838
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20230330_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20230330_pre.xml EX-101.PRE 10804
6 EXTRACTED XBRL INSTANCE DOCUMENT d491593d8k_htm.xml XML 3229
Mailing Address 8030 EL RIO STREET HOUSTON TX 77054
Business Address 8030 EL RIO STREET HOUSTON TX 77054 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 23790681
SIC: 2834 Pharmaceutical Preparations